1. In Vivo
  2. >>Business Strategy

Abbott Moves One Way in Cardiovascular Devices, Another in Orthopedics, To Get To the Same Place

Abbott Laboratories broke into the spinal market with its acquisition of Spinal Concepts, and expanded its interventional cardiology product line by acquiring Jomed's coronary and peripheral interventional product lines. Both deals reflect the increasing convergence in medical devices of drug and device therapies.

Rumors about Abbott Laboratories Inc. 's acquisition of struggling European cardiovascular device company Jomed NV [See Deal] were all over this year's Paris Course on Revascularization (PCR) meeting, held in early May just weeks before the news officially broke. One report had Abbott paying a significant premium for the troubled company, well more than it's estimated break-up value of $75 million. Another report had Abbott and Jomed doing a three-way deal with vulnerable plaque start-up Volcano Therapeutics Inc. , with the latter walking off with the intravascular ultrasound (IVUS) business Jomed got when it acquired EndoSonics Corp. a couple of years ago [See Deal].

Of course, Abbott's eventual price paid, nearly $71 million plus the assumption of some liability (more than $20 million), was closer to the industry consensus on Jomed than to any...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

More from In Vivo

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.